LEO Pharma A/S, a global leader in medical dermatology, today announced the positive results from a 16-week interim analysis of the Phase 3b ADHAND trial evaluating tralokinumab for the treatment of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback